Fig. 2: Correlation of ctDNA and CMC with response to treatment, PFS and OS. | npj Precision Oncology

Fig. 2: Correlation of ctDNA and CMC with response to treatment, PFS and OS.

From: A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance

Fig. 2

a Violin plot illustrating the amount of ctDNA (copies/ml of plasma) at T0 in responders vs non-responders/early progressing patients (Mann–Whitney U test, p = 0.039). First and third quartile, together with the median (middle line) are indicated in the plot. Contingency table with corresponding Fisher’s exact test p value is indicated below the graph. R, responding; NR, not responding; EP, early progressing patients (PFS ≤ 6 months). Kaplan–Meier plots of (b) OS according to BRAF-mutant ctDNA clearance at the first observational point after treatment start (range 2–6 months); (c) PFS and (d) OS according to baseline pTERT-mutant ctDNA amount; (e) PFS and (f) OS according to CMC count at baseline. The violin plot was performed using GraphPad version 8.0 for Windows (GraphPad Software Inc., San Diego, CA, USA).

Back to article page